Tag Archives: Ultra Orphan

First Orphan Launch a Challenge for AstraZeneca

By Ben Comer | Published: August 2, 2011
Four months after AstraZeneca received FDA approval for vandetanib, a treatment for inoperable medullary thyroid cancer, the company announced the drug’s trade name: Caprelsa. FDA said other proposed names – Zactima, for example – too closely resembled other currently marketed proprietary names. Getting FDA approval on a brand name for vandetanib, AstraZeneca’s very first orphan drug, isn’t [...]
Posted in FDA, Marketing, Safety, Strategy, patient education | Also tagged , , , , | Leave a comment

AstraZeneca Signs Exclusive Distribution Deal for Vandetanib

By Ben Comer | Published: April 27, 2011
As the number of drugs targeting small populations increases, managing numerous drug distribution channels and educating the relevant parties – specialty pharmacists, payers, physicians, and patients – becomes a daunting task. Specialty pharmacies that handle seven to 10 major disease states, after all, might only see three or four patients with a given rare disease, [...]
Posted in Deals, FDA, Legal, Market Access, Regulatory, Strategy, healthcare, pricing | Also tagged , , | Leave a comment

Linguistics: "Salami-slicing" Orphan Drugs

By Joanna Breitstein | Published: October 23, 2008
Ultra-orphan? It’s a phrase I never heard before, but increasingly, companies are taking it on and finding it a useful way to describe the very smallest patient groups. “Language is very important, and you have to understand how it affects perception,” says Maria Hardin, vice president of patient services for NORD (National Organization for Rare Diseases). [...]
Posted in Events | Also tagged , , , , | 1 Comment